Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate

Doravirine is a nonnucleoside reverse transcriptase inhibitor that has been approved for the treatment of HIV-1. In a phase 1 trial, doravirine exposure was transiently decreased when treatment was started immediately after the cessation of efavirenz treatment. In a post hoc subgroup analysis of par...

Descripción completa

Detalles Bibliográficos
Autores principales: Greaves, Wayne, Wan, Hong, Yee, Ka Lai, Kandala, Bhargava, Vaddady, Pavan, Hwang, Carey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879224/
https://www.ncbi.nlm.nih.gov/pubmed/31548188
http://dx.doi.org/10.1128/AAC.01298-19
Descripción
Sumario:Doravirine is a nonnucleoside reverse transcriptase inhibitor that has been approved for the treatment of HIV-1. In a phase 1 trial, doravirine exposure was transiently decreased when treatment was started immediately after the cessation of efavirenz treatment. In a post hoc subgroup analysis of participants who switched from an efavirenz-based regimen to doravirine-lamivudine-tenofovir disoproxil fumarate in the phase 3 DRIVE-SHIFT trial, doravirine plasma levels at week 4 were similar to noninduced levels, and HIV-1 suppression was maintained at weeks 24 and 48.

Ejemplares similares